Wednesday, Panacos Pharmaceuticals, Inc., a biotechnology company, revealed data from studies on HIV Drug Resistance Program that indicated lack of rapid emergence of resistance to bevirimat in single multiple dose monotherapy studies in HIV infected patients. Bevirimat is a lead drug candidate of the company and is designed to act potently against a broad range of HIV, including strains that are resistant to existing classes of drugs. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/280312/)